Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
special purpose acquisition company
Biotech
Why Corxel picked SPAC route to take obesity biotech public
Corxel may not have always planned to dust off the SPAC route to the public markets, but the obesity-focused biotech is happy with its choice.
Marissa Russo
Oct 27, 2026 6:00am
TCGX picks migraine biotech TriGemX to take public via SPAC
Oct 19, 2026 11:05am
City scores $200M IPO as Frazier takes biotech SPAC to Nasdaq
Oct 16, 2026 2:47am
JATT mastermind launches latest biotech-focused SPAC in $60M IPO
Aug 26, 2026 9:45am
RA Capital launches Oak Hill Bio onto the Nasdaq via SPAC
Jul 27, 2026 3:25pm
Talawar heads to Nasdaq via SPAC deal to fund eczema bispecific
Jun 29, 2026 7:00am